About AlphaCognition
AlphaCognition is a company based in Vancouver (Canada) founded in 2000.. AlphaCognition offers products and services including ZUNVEYL. AlphaCognition operates in a competitive market with competitors including T3D Therapeutics, Alzheon, Longeveron, Alchemab and Cerecin, among others.
- Headquarter Vancouver, Canada
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Alpha Cognition Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-14.64 M-6.28as on Dec 31, 2024
-
EBITDA
$-11.83 M-20.84as on Dec 31, 2024
-
Latest Funding Round
$4.55 M (USD), Post-IPO
Sep 24, 2024
-
Investors
Manchester Capital Management
& 1 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of AlphaCognition
AlphaCognition is a publicly listed company on the NASDAQ with ticker symbol ACOG in USA, operating in the Finance sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of AlphaCognition
AlphaCognition offers a comprehensive portfolio of products and services, including ZUNVEYL. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Cholinesterase inhibitor for treating mild to moderate Alzheimer's disease in adults.
Unlock access to complete
Funding Insights of AlphaCognition
- Total Funding Total Funding
- Total Rounds 11
- Last Round Post-IPO — $4.5M
-
First Round
First Round
(29 Apr 2020)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2024 | Amount | Post-IPO - AlphaCognition | Valuation |
investors |
|
| Jan, 2024 | Amount | Post-IPO - AlphaCognition | Valuation |
investors |
|
| Dec, 2023 | Amount | Post-IPO - AlphaCognition | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in AlphaCognition
AlphaCognition has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Manchester Capital Management and Military Health. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Administers health care and support for military personnel and operations.
|
Founded Year | Domain | Location | |
|
Multi-family office services are provided for wealth management.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by AlphaCognition
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - AlphaCognition
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Alphacognition Comparisons
Competitors of AlphaCognition
AlphaCognition operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as T3D Therapeutics, Alzheon, Longeveron, Alchemab and Cerecin, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for neurodegenerative diseases, including Alzheimer's, are developed.
|
|
| domain | founded_year | HQ Location |
Oral inhibitors of amyloid aggregation for Alzheimer's treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cellular therapies for aging-related and life-threatening conditions are developed.
|
|
| domain | founded_year | HQ Location |
Developer of antibody based therapeutics to treat cancers, neurodegenerative conditions and infectious diseases
|
|
| domain | founded_year | HQ Location |
Medical foods and drugs for Alzheimer's disease are developed.
|
|
| domain | founded_year | HQ Location |
Genome-scale drug discovery platform is provided for treating multiple diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Alphacognition
Frequently Asked Questions about AlphaCognition
When was AlphaCognition founded?
AlphaCognition was founded in 2000 and raised its 1st funding round 20 years after it was founded.
Where is AlphaCognition located?
AlphaCognition is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
Who is the current CEO of AlphaCognition?
Michael Mcfadden is the current CEO of AlphaCognition.
What does AlphaCognition do?
AlphaCognition was founded in 2000 in Vancouver, Canada, within the biotechnology sector. Focus is placed on developing therapeutics for neurological disorders affecting the brain and spinal cord. A patented chemical entity known as Alpha-1062, functioning as an acetylcholine esterase inhibitor, has been advanced for Alzheimers disease treatment, with human trials completed. Additionally, Alpha-602 has been created to address ALS.
Who are the top competitors of AlphaCognition?
AlphaCognition's top competitors include Alzheon, Longeveron and Alchemab.
What products or services does AlphaCognition offer?
AlphaCognition offers ZUNVEYL.
Is AlphaCognition publicly traded?
Yes, AlphaCognition is publicly traded on NASDAQ under the ticker symbol ACOG.
Who are AlphaCognition's investors?
AlphaCognition has 2 investors. Key investors include Manchester Capital Management, and Military Health.
What is AlphaCognition's ticker symbol?
The ticker symbol of AlphaCognition is ACOG on NASDAQ.